|
|
News Breaks
|
October 12, 2009
|
| 06:31 EDT |  | RPTPD |
| theflyonthewall.com: | Raptor Pharmaceuticals announces positive Phase IIa data | | Raptor Pharmaceutical announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate in adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 2% to 5% of the U.S. population. At the completion of the initial six-month treatment phase, the study achieved the primary endpoint: mean blood levels of alanine aminotransferase, a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase. :theflyonthewall.com |
|
|
News For RPTPD From The Last 14 Days Check below for free stories on RPTPD the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
